https://biotechmorning.com/news/intrabio-first-drug-ataxia-telangiectasia Biotech Morning en 2026-07-07T14:29:57.932Z The First Drug That Could Actually Treat This Childhood Disease Nobody Talks About https://biotechmorning.com/news/doctors-sue-cdc-childhood-vaccine-schedule Biotech Morning en 2026-07-07T14:29:07.632Z Doctors Just Took the CDC to Court Over Your Kid's Vaccine Schedule https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-duchenne Biotech Morning en 2026-07-07T14:28:13.988Z Sarepta's Worst Week: A Black Box, 500 Pink Slips, and No Easy Answers https://biotechmorning.com/news/gilead-tubulis-5-billion-adc-acquisition-3 Biotech Morning en 2026-07-07T14:27:20.072Z Gilead Just Paid $5 Billion for a Company That Raised €10.7M Six Years Ago https://biotechmorning.com/news/vertex-10-billion-crinetics-endocrinology-deal Biotech Morning en 2026-07-07T14:26:27.207Z Vertex Just Bet $10 Billion on a Body Part Nobody Talks About https://biotechmorning.com/news/jnj-shrugs-off-mfn-drug-pricing Biotech Morning en 2026-07-07T14:25:28.261Z J&J Just Shrugged Off the Government's Drug Pricing Hammer https://biotechmorning.com/news/genentech-layoffs-breast-cancer-deal Biotech Morning en 2026-07-07T14:24:29.707Z Genentech Cut 103 Jobs and Wrote a $490M Check on the Same Day https://biotechmorning.com/news/scribe-therapeutics-ipo-gene-editing-cholesterol Biotech Morning en 2026-07-07T14:23:33.495Z The Gene Editing Company That Wants to Replace Your Cholesterol Meds https://biotechmorning.com/news/novartis-myricx-bio-adc-acquisition Biotech Morning en 2026-07-07T14:22:37.298Z Novartis Just Dropped $1.1B on a Company With Zero Clinical Data https://biotechmorning.com/news/40-year-drought-aatd-sanofi-wave Biotech Morning en 2026-07-06T14:25:44.277Z The 40-Year Drought That Two Companies Are Racing to End https://biotechmorning.com/news/big-pharma-trump-pricing-deals-tariff-relief Biotech Morning en 2026-07-06T14:24:55.849Z Big Pharma Just Got a Hall Pass (With Strings Attached) https://biotechmorning.com/news/regeneron-parabilis-2-3-billion-helicon-deal Biotech Morning en 2026-07-06T14:24:12.294Z The $2.3B Bet on a Drug That's Not Quite an ADC https://biotechmorning.com/news/roche-divarasib-beats-amgen-bms-kras-lung-cancer Biotech Morning en 2026-07-06T14:23:26.129Z Roche Just Beat Both Rivals in KRAS Lung Cancer. At the Same Time. https://biotechmorning.com/news/immunovant-fcrn-inhibitor-eye-disease-failure Biotech Morning en 2026-07-06T14:22:40.640Z A Lesson About Antibodies and Eyeballs https://biotechmorning.com/news/lilly-engage-biologics-tethosome-non-viral-dna-delivery Biotech Morning en 2026-07-06T14:21:56.741Z Lilly's $202M Bet on a Protein That Sneaks DNA Past Your Immune System https://biotechmorning.com/news/denmark-861m-bet-europes-biotech-capital Biotech Morning en 2026-07-06T14:21:11.943Z Denmark's $861M Bet to Become Europe's Biotech Capital https://biotechmorning.com/news/biomarin-270m-inozyme-phase-3-failure Biotech Morning en 2026-07-06T14:20:37.167Z BioMarin Spent $270M on a Drug That Works in the Blood but Not in the Bones https://biotechmorning.com/news/regeneron-fianlimab-keytruda-melanoma-phase-3-failure Biotech Morning en 2026-07-06T14:19:54.821Z Regeneron Just Got Schooled by the Drug It Was Trying to Beat